Različice SARS-CoV-2 (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Različice SARS-CoV-2" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

23nih.gov

4^th place

8^th place

18doi.org

2^nd place

5^th place

8web.archive.org

1^st place

2^nd place

5semanticscholar.org

11^th place

51^st place

5who.int

195^th place

64^th place

4cdc.gov

218^th place

83^rd place

4nextstrain.org

low place

3cov-lineages.org

low place

3gisaid.org

low place

2bbc.com

20^th place

70^th place

2medrxiv.org

low place

2statnews.com

8,771^st place

7,096^th place

2gov.uk

432^nd place

1,914^th place

2nytimes.com

7^th place

37^th place

2ssi.dk

low place

1nijz.si

low place

229^th place

1sciencemag.org

857^th place

207^th place

1covariants.org

low place

1ctvnews.ca

768^th place

4,470^th place

1twitter.com

23^rd place

159^th place

1github.com

383^rd place

5,873^rd place

1nzherald.co.nz

435^th place

2,105^th place

1wionews.com

2,596^th place

low place

1independent.co.uk

36^th place

119^th place

1abc.net.au

139^th place

516^th place

1theconversation.com

928^th place

3,462^nd place

1newscientist.com

774^th place

453^rd place

1virological.org

low place

1europa.eu

68^th place

28^th place

1nsw.gov.au

640^th place

944^th place

1harvard.edu

18^th place

31^st place

1nature.com

234^th place

148^th place

1usatoday.com

41^st place

156^th place

1reuters.com

49^th place

97^th place

abc.net.au

»What is the Mu variant of COVID-19?«. www.abc.net.au (v angleščini). 1. september 2021. Pridobljeno 1. septembra 2021.

bbc.com

»Coronavirus variants and mutations: The science explained«. BBC News (v britanski angleščini). 6. januar 2021. Pridobljeno 2. februarja 2021.
»Covid: WHO renames UK and other variants with Greek letters« (v angleščini). Pridobljeno 7. julija 2021.

cdc.gov

»Science Brief: Emerging SARS-CoV-2 Variants«. CDC. 28. januar 2021. Pridobljeno 8. julija 2021.
»SARS-CoV-2 Variant Classifications and Definitions«. CDC.gov. Centers for Disease Control and Prevention. 29. junij 2021. Redno se posodablja.
»SARS-CoV-2 Variant Classifications and Definitions«. CDC.gov. Centers for Disease Control and Prevention. 11. februar 2020. Arhivirano iz spletišča dne 29. junija 2021. Pridobljeno 18. junija 2021. Se redno posodablja.
»Emerging SARS-CoV-2 Variants«. CDC.gov (Science brief). Centers for Disease Control and Prevention. 28. januar 2021. Pridobljeno 4. januarja 2021. Članek vsebuje besedilo iz tega vira, ki je v javni domeni.

cov-lineages.org

»PANGO lineages-Lineage B.1.1.28«. cov-lineages.org. Pridobljeno 4. februarja 2021.^{[neuspešno preverjanje]}
»Lineage descriptions«. cov-lineages.org. Pango team.
»B.1.525 international lineage report«. cov-lineages.org. Pango team. 19. maj 2021. Arhivirano iz spletišča dne 9. junija 2021. Pridobljeno 16. februarja 2021.

covariants.org

»Variant: 20J/501Y.V3«. covariants.org. 1. april 2021. Pridobljeno 6. aprila 2021.

ctvnews.ca

Flanagan R (2. februar 2021). »Why the WHO won't call it the 'U.K. variant', and you shouldn't either«. CTV News (v angleščini). Pridobljeno 12. februarja 2021.

doi.org

Shahhosseini, Nariman; Babuadze, George; Wong, Gary; Kobinger, Gary (2021). »Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern«. Microorganisms. 9 (5): 926. doi:10.3390/microorganisms9050926. PMC 8146828. PMID 33925854. S2CID 233460887.
Kupferschmidt K (15. januar 2021). »New coronavirus variants could cause more reinfections, require updated vaccines«. Science. doi:10.1126/science.abg6028. Pridobljeno 2. februarja 2021.
Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, in sod. (november 2020). »A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology«. Nature Microbiology. 5 (11): 1403–1407. doi:10.1038/s41564-020-0770-5. PMC 7610519. PMID 32669681. S2CID 220544096.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava) Cited in (Alm et al.)
Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, in sod. (The WHO European Region sequencing laboratories and GISAID EpiCoV group) (Avgust 2020). »Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020«. Euro Surveillance. 25 (32). doi:10.2807/1560-7917.ES.2020.25.32.2001410. PMC 7427299. PMID 32794443.
Zhukova A, Blassel L, Lemoine F, Morel M, Voznica J, Gascuel O (november 2020). »Origin, evolution and global spread of SARS-CoV-2«. Comptes Rendus Biologies. 344: 57–75. doi:10.5802/crbiol.29. PMID 33274614.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Koyama T, Platt D, Parida L (Julij 2020). »Variant analysis of SARS-CoV-2 genomes«. Bulletin of the World Health Organization. 98 (7): 495–504. doi:10.2471/BLT.20.253591. PMC 7375210. PMID 32742035. We detected in total 65776 variants with 5775 distinct variants.
Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, in sod. (Marec 2021). »Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology«. Nature Microbiology. 6 (3): 415. doi:10.1038/s41564-021-00872-5. PMC 7845574. PMID 33514928.
Shahhosseini, Nariman; Babuadze, George (Giorgi); Wong, Gary; Kobinger, Gary P. (Maj 2021). »Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern«. Microorganisms (v angleščini). 9 (5): 926. doi:10.3390/microorganisms9050926. PMC 8146828. PMID 33925854.
Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, in sod. (Junij 2021). »Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021«. Euro Surveillance. 26 (24): 2100509. doi:10.2807/1560-7917.ES.2021.26.24.2100509. PMC 8212592. PMID 34142653.
Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, in sod. (Junij 2021). »Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis«. BMJ. 373: n1412. doi:10.1136/bmj.n1412. PMC 8204098. PMID 34130987. S2CID 235187479.
Collier DA, De Marco A, Ferreira IA, Meng B, Datir RP, Walls AC, in sod. (Maj 2021). »Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies«. Nature (Published). 593 (7857): 136–141. doi:10.1038/s41586-021-03412-7. PMID 33706364. We therefore generated pseudoviruses that carried the B.1.1.7 spike mutations with or without the additional E484K substitution and tested these against sera obtained after the first and second dose of the BNT162b2 mRNA vaccine as well as against convalescent sera. After the second vaccine dose, we observed a considerable loss of neutralising activity for the pseudovirus with the B.1.1.7 spike mutations and E484K (Fig. 3d, e). The mean fold change for the E484K-containing B.1.1.7 spike variant was 6.7 compared with 1.9 for the B.1.1.7 variant, relative to the wild-type spike protein (Fig. 3a–c and Extended Data Fig. 5). Similarly, when we tested a panel of convalescent sera with a range of neutralisation titres (Fig. 1f, g and Extended Data Fig. 5), we observed additional loss of activity against the mutant B.1.1.7 spike with E484K, with fold change of 11.4 relative to the wild-type spike protein (Fig. 3f, g and Extended Data Fig. 5).
Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DD, Mishra S, in sod. (Maj 2021). »Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil«. Science. 372 (6544): 815–821. Bibcode:2021Sci...372..815F. doi:10.1126/science.abh2644. PMC 8139423. PMID 33853970. Within this plausible region of parameter space, P.1 can be between 1.7 and 2.4 times more transmissible (50% BCI, 2.0 median, with a 99% posterior probability of being >1) than local non-P1 lineages and can evade 21 to 46% (50% BCI, 32% median, with a 95% posterior probability of being able to evade at least 10%) of protective immunity elicited by previous infection with non-P.1 lineages, corresponding to 54 to 79% (50% BCI, 68% median) cross-immunity ... We estimate that infections are 1.2 to 1.9 times more likely (50% BCI, median 1.5, 90% posterior probability of being >1) to result in mortality in the period after the emergence of P.1, compared with before, although posterior estimates of this relative risk are also correlated with inferred cross-immunity. More broadly, the recent epidemic in Manaus has strained the city's health care system, leading to inadequate access to medical care. We therefore cannot determine whether the estimated increase in relative mortality risk is due to P.1 infection, stresses on the Manaus health care system, or both. Detailed clinical investigations of P.1 infections are needed.
Freitas AR, Lemos DR, Beckedorff OA, Cavalcanti LP, Siqueira AM, Mello RC, in sod. (19. april 2021). »The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P.1 was greater among young adults without pre-existing risk conditions«. medRxiv (Preprint). doi:10.1101/2021.04.13.21255281. S2CID 233295278. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95% CI, 2.9-11.03; p <0.0001) and in the age group of 40 and 59 years old, this risk was 7.7 times higher (95% CI, 5.01-11.83; p <0.0001) comparing with November–December. ... The heterogeneity observed between the age groups was greater when we analysed the subgroup of the population without preexisting risk conditions where we found that the CFR in the female sex in the second wave was 1.95 times (95% CI, 1.38-2.76) the CFR of the first wave in the population over 85 years old and was 7.7 times (95% CI, 5.01-11.83; p < 0.0001) in the population between 40 and 59 years old. In the male population without previous diseases, the CFR in the second wave was 2.18 (95% CI, 1.62-2.93) times the CFR of the first wave in the population over 85 years old and 5.9 (95% CI, 3.2-10.85; p < 0, 0001) higher in the range between 20 and 39 years old.
Sheikh A, McMenamin J, Taylor B, Robertson C (Junij 2021). »SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness«. Lancet. 397 (10293): 2461–2462. doi:10.1016/S0140-6736(21)01358-1. PMC 8201647. PMID 34139198.
Fisman D, Tuite A (12. julij 2021). »Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada«. medRxiv (Preprint). doi:10.1101/2021.07.05.21260050. S2CID 235756602.
Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, in sod. (Maj 2021). »Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees«. Clinical Infectious Diseases. Oxford University Press (ciab411). bioRxiv 10.1101/2021.04.23.441101. doi:10.1093/cid/ciab411. PMID 33961693.
Callaway, Ewen (25. november 2021). »Heavily mutated coronavirus variant puts scientists on alert«. Nature. doi:10.1038/d41586-021-03552-w.

dx.doi.org

"Emergence of a novel SARS-CoV-2 strain in Southern California, USA". medRxiv. 2021. doi:10.1101/2021.01.18.21249786 . https://www.medrxiv.org/content/10.1101/2021.01.18.21249786v1.

europa.eu

ecdc.europa.eu

»SARS-CoV-2 variants of concern«. ECDC.eu. European Centre for Disease Prevention and Control. Arhivirano iz spletišča dne 16. junija 2021. Pridobljeno 12. maja 2021. USe redno posodablja.

gisaid.org

»clade tree (from 'Clade and lineage nomenclature')«. GISAID. 4. julij 2020. Pridobljeno 7. januarja 2021.
»Global phylogeny, updated by Nextstrain«. GISAID. 18. januar 2021. Pridobljeno 19. januarja 2021.
»GISAID hCOV19 Variants (see menu option 'G/484K.V3 (B.1.525)')«. GISAID. Pridobljeno 4. marca 2021.{{navedi splet}}: Vzdrževanje CS1: url-status (povezava)

github.com

»cov-lineages/pangolin: Software package for assigning SARS-CoV-2 genome sequences to global lineages«. Github. Pridobljeno 2. januarja 2021.

gov.uk

»Variants: distribution of cases data«. Public Health England. Government Digital Service. Arhivirano iz spletišča dne 7. junija 2021. Pridobljeno 16. februarja 2021.
»Confirmed cases of COVID-19 variants identified in UK«. GOV.UK. Public Health England. 15. januar 2021.

harvard.edu

ui.adsabs.harvard.edu

Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DD, Mishra S, in sod. (Maj 2021). »Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil«. Science. 372 (6544): 815–821. Bibcode:2021Sci...372..815F. doi:10.1126/science.abh2644. PMC 8139423. PMID 33853970. Within this plausible region of parameter space, P.1 can be between 1.7 and 2.4 times more transmissible (50% BCI, 2.0 median, with a 99% posterior probability of being >1) than local non-P1 lineages and can evade 21 to 46% (50% BCI, 32% median, with a 95% posterior probability of being able to evade at least 10%) of protective immunity elicited by previous infection with non-P.1 lineages, corresponding to 54 to 79% (50% BCI, 68% median) cross-immunity ... We estimate that infections are 1.2 to 1.9 times more likely (50% BCI, median 1.5, 90% posterior probability of being >1) to result in mortality in the period after the emergence of P.1, compared with before, although posterior estimates of this relative risk are also correlated with inferred cross-immunity. More broadly, the recent epidemic in Manaus has strained the city's health care system, leading to inadequate access to medical care. We therefore cannot determine whether the estimated increase in relative mortality risk is due to P.1 infection, stresses on the Manaus health care system, or both. Detailed clinical investigations of P.1 infections are needed.

independent.co.uk

»Lambda variant: What is the new strain of Covid detected in the UK?«.

medrxiv.org

"Emergence of a novel SARS-CoV-2 strain in Southern California, USA". medRxiv. 2021. doi:10.1101/2021.01.18.21249786 . https://www.medrxiv.org/content/10.1101/2021.01.18.21249786v1.
Freitas AR, Lemos DR, Beckedorff OA, Cavalcanti LP, Siqueira AM, Mello RC, in sod. (19. april 2021). »The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P.1 was greater among young adults without pre-existing risk conditions«. medRxiv (Preprint). doi:10.1101/2021.04.13.21255281. S2CID 233295278. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95% CI, 2.9-11.03; p <0.0001) and in the age group of 40 and 59 years old, this risk was 7.7 times higher (95% CI, 5.01-11.83; p <0.0001) comparing with November–December. ... The heterogeneity observed between the age groups was greater when we analysed the subgroup of the population without preexisting risk conditions where we found that the CFR in the female sex in the second wave was 1.95 times (95% CI, 1.38-2.76) the CFR of the first wave in the population over 85 years old and was 7.7 times (95% CI, 5.01-11.83; p < 0.0001) in the population between 40 and 59 years old. In the male population without previous diseases, the CFR in the second wave was 2.18 (95% CI, 1.62-2.93) times the CFR of the first wave in the population over 85 years old and 5.9 (95% CI, 3.2-10.85; p < 0, 0001) higher in the range between 20 and 39 years old.

nature.com

Callaway, Ewen (25. november 2021). »Heavily mutated coronavirus variant puts scientists on alert«. Nature. doi:10.1038/d41586-021-03552-w.

newscientist.com

Le Page, Michael (4. junij 2021). »Indian covid-19 variant (B.1.617)«. New Scientist. Pridobljeno 8. junija 2021.

nextstrain.org

Bedford T, Hodcroft B, Neher RA (6. januar 2021). »Updated Nextstrain SARS-CoV-2 clade naming strategy«. nextstrain.org. Pridobljeno 19. januarja 2021.
»Genomic epidemiology of novel coronavirus – Global subsampling (Filtered to B.1.617)«. nextstrain.org. Pridobljeno 5. maja 2021.{{navedi splet}}: Vzdrževanje CS1: url-status (povezava)
»Nextstrain COVID-19«. Nextstrain. Pridobljeno 1. januarja 2021.{{navedi splet}}: Vzdrževanje CS1: url-status (povezava)

clades.nextstrain.org

»Nextclade« (What are the clades?). nextstrain.org. Arhivirano iz spletišča dne 19. januarja 2021. Pridobljeno 19. januarja 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Shahhosseini, Nariman; Babuadze, George; Wong, Gary; Kobinger, Gary (2021). »Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern«. Microorganisms. 9 (5): 926. doi:10.3390/microorganisms9050926. PMC 8146828. PMID 33925854. S2CID 233460887.
Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, in sod. (november 2020). »A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology«. Nature Microbiology. 5 (11): 1403–1407. doi:10.1038/s41564-020-0770-5. PMC 7610519. PMID 32669681. S2CID 220544096.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava) Cited in (Alm et al.)
Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, in sod. (The WHO European Region sequencing laboratories and GISAID EpiCoV group) (Avgust 2020). »Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020«. Euro Surveillance. 25 (32). doi:10.2807/1560-7917.ES.2020.25.32.2001410. PMC 7427299. PMID 32794443.
Zhukova A, Blassel L, Lemoine F, Morel M, Voznica J, Gascuel O (november 2020). »Origin, evolution and global spread of SARS-CoV-2«. Comptes Rendus Biologies. 344: 57–75. doi:10.5802/crbiol.29. PMID 33274614.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Koyama T, Platt D, Parida L (Julij 2020). »Variant analysis of SARS-CoV-2 genomes«. Bulletin of the World Health Organization. 98 (7): 495–504. doi:10.2471/BLT.20.253591. PMC 7375210. PMID 32742035. We detected in total 65776 variants with 5775 distinct variants.
Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, in sod. (Marec 2021). »Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology«. Nature Microbiology. 6 (3): 415. doi:10.1038/s41564-021-00872-5. PMC 7845574. PMID 33514928.
Shahhosseini, Nariman; Babuadze, George (Giorgi); Wong, Gary; Kobinger, Gary P. (Maj 2021). »Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern«. Microorganisms (v angleščini). 9 (5): 926. doi:10.3390/microorganisms9050926. PMC 8146828. PMID 33925854.
Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, in sod. (Junij 2021). »Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021«. Euro Surveillance. 26 (24): 2100509. doi:10.2807/1560-7917.ES.2021.26.24.2100509. PMC 8212592. PMID 34142653.
Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, in sod. (Junij 2021). »Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis«. BMJ. 373: n1412. doi:10.1136/bmj.n1412. PMC 8204098. PMID 34130987. S2CID 235187479.
Collier DA, De Marco A, Ferreira IA, Meng B, Datir RP, Walls AC, in sod. (Maj 2021). »Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies«. Nature (Published). 593 (7857): 136–141. doi:10.1038/s41586-021-03412-7. PMID 33706364. We therefore generated pseudoviruses that carried the B.1.1.7 spike mutations with or without the additional E484K substitution and tested these against sera obtained after the first and second dose of the BNT162b2 mRNA vaccine as well as against convalescent sera. After the second vaccine dose, we observed a considerable loss of neutralising activity for the pseudovirus with the B.1.1.7 spike mutations and E484K (Fig. 3d, e). The mean fold change for the E484K-containing B.1.1.7 spike variant was 6.7 compared with 1.9 for the B.1.1.7 variant, relative to the wild-type spike protein (Fig. 3a–c and Extended Data Fig. 5). Similarly, when we tested a panel of convalescent sera with a range of neutralisation titres (Fig. 1f, g and Extended Data Fig. 5), we observed additional loss of activity against the mutant B.1.1.7 spike with E484K, with fold change of 11.4 relative to the wild-type spike protein (Fig. 3f, g and Extended Data Fig. 5).
Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DD, Mishra S, in sod. (Maj 2021). »Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil«. Science. 372 (6544): 815–821. Bibcode:2021Sci...372..815F. doi:10.1126/science.abh2644. PMC 8139423. PMID 33853970. Within this plausible region of parameter space, P.1 can be between 1.7 and 2.4 times more transmissible (50% BCI, 2.0 median, with a 99% posterior probability of being >1) than local non-P1 lineages and can evade 21 to 46% (50% BCI, 32% median, with a 95% posterior probability of being able to evade at least 10%) of protective immunity elicited by previous infection with non-P.1 lineages, corresponding to 54 to 79% (50% BCI, 68% median) cross-immunity ... We estimate that infections are 1.2 to 1.9 times more likely (50% BCI, median 1.5, 90% posterior probability of being >1) to result in mortality in the period after the emergence of P.1, compared with before, although posterior estimates of this relative risk are also correlated with inferred cross-immunity. More broadly, the recent epidemic in Manaus has strained the city's health care system, leading to inadequate access to medical care. We therefore cannot determine whether the estimated increase in relative mortality risk is due to P.1 infection, stresses on the Manaus health care system, or both. Detailed clinical investigations of P.1 infections are needed.
Sheikh A, McMenamin J, Taylor B, Robertson C (Junij 2021). »SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness«. Lancet. 397 (10293): 2461–2462. doi:10.1016/S0140-6736(21)01358-1. PMC 8201647. PMID 34139198.
Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, in sod. (Maj 2021). »Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees«. Clinical Infectious Diseases. Oxford University Press (ciab411). bioRxiv 10.1101/2021.04.23.441101. doi:10.1093/cid/ciab411. PMID 33961693.

ncbi.nlm.nih.gov

Shahhosseini, Nariman; Babuadze, George; Wong, Gary; Kobinger, Gary (2021). »Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern«. Microorganisms. 9 (5): 926. doi:10.3390/microorganisms9050926. PMC 8146828. PMID 33925854. S2CID 233460887.
Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, in sod. (november 2020). »A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology«. Nature Microbiology. 5 (11): 1403–1407. doi:10.1038/s41564-020-0770-5. PMC 7610519. PMID 32669681. S2CID 220544096.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava) Cited in (Alm et al.)
Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, in sod. (The WHO European Region sequencing laboratories and GISAID EpiCoV group) (Avgust 2020). »Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020«. Euro Surveillance. 25 (32). doi:10.2807/1560-7917.ES.2020.25.32.2001410. PMC 7427299. PMID 32794443.
Koyama T, Platt D, Parida L (Julij 2020). »Variant analysis of SARS-CoV-2 genomes«. Bulletin of the World Health Organization. 98 (7): 495–504. doi:10.2471/BLT.20.253591. PMC 7375210. PMID 32742035. We detected in total 65776 variants with 5775 distinct variants.
Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, in sod. (Marec 2021). »Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology«. Nature Microbiology. 6 (3): 415. doi:10.1038/s41564-021-00872-5. PMC 7845574. PMID 33514928.
Shahhosseini, Nariman; Babuadze, George (Giorgi); Wong, Gary; Kobinger, Gary P. (Maj 2021). »Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern«. Microorganisms (v angleščini). 9 (5): 926. doi:10.3390/microorganisms9050926. PMC 8146828. PMID 33925854.
Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, in sod. (Junij 2021). »Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021«. Euro Surveillance. 26 (24): 2100509. doi:10.2807/1560-7917.ES.2021.26.24.2100509. PMC 8212592. PMID 34142653.
Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, in sod. (Junij 2021). »Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis«. BMJ. 373: n1412. doi:10.1136/bmj.n1412. PMC 8204098. PMID 34130987. S2CID 235187479.
Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DD, Mishra S, in sod. (Maj 2021). »Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil«. Science. 372 (6544): 815–821. Bibcode:2021Sci...372..815F. doi:10.1126/science.abh2644. PMC 8139423. PMID 33853970. Within this plausible region of parameter space, P.1 can be between 1.7 and 2.4 times more transmissible (50% BCI, 2.0 median, with a 99% posterior probability of being >1) than local non-P1 lineages and can evade 21 to 46% (50% BCI, 32% median, with a 95% posterior probability of being able to evade at least 10%) of protective immunity elicited by previous infection with non-P.1 lineages, corresponding to 54 to 79% (50% BCI, 68% median) cross-immunity ... We estimate that infections are 1.2 to 1.9 times more likely (50% BCI, median 1.5, 90% posterior probability of being >1) to result in mortality in the period after the emergence of P.1, compared with before, although posterior estimates of this relative risk are also correlated with inferred cross-immunity. More broadly, the recent epidemic in Manaus has strained the city's health care system, leading to inadequate access to medical care. We therefore cannot determine whether the estimated increase in relative mortality risk is due to P.1 infection, stresses on the Manaus health care system, or both. Detailed clinical investigations of P.1 infections are needed.
Sheikh A, McMenamin J, Taylor B, Robertson C (Junij 2021). »SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness«. Lancet. 397 (10293): 2461–2462. doi:10.1016/S0140-6736(21)01358-1. PMC 8201647. PMID 34139198.

nijz.si

»Delta bolj nalezljiva od drugih različic virusa SARS-CoV-2«. NIJZ. 1. julij 2021. Arhivirano iz prvotnega spletišča dne 7. julija 2021. Pridobljeno 8. julija 2021.

nsw.gov.au

aci.health.nsw.gov.au

»Living Evidence – SARS-CoV-2 variants«. Agency for Clinical Innovation. nsw.gov.au. Ministry of Health (New South Wales). 23. julij 2021. Arhivirano iz spletišča dne 16. aprila 2021. Pridobljeno 22. marca 2021. Se redno posodablja..

nytimes.com

Mandavilli A (24. februar 2021). »A New Coronavirus Variant Is Spreading in New York, Researchers Report«. The New York Times.
Zimmer, Carl; Mandavilli, Apoorva (14. maj 2021). »How the United States Beat the Variants, for Now«. New York Times. Pridobljeno 17. maja 2021.

nzherald.co.nz

»Covid 19 coronavirus: Ultra-contagious Lambda variant detected in Australia«.

reuters.com

»Pfizer shot less effective against hospitalisation in South Africa - study«. 14. december 2021. Pridobljeno 14. decembra 2021.

sciencemag.org

Kupferschmidt K (15. januar 2021). »New coronavirus variants could cause more reinfections, require updated vaccines«. Science. doi:10.1126/science.abg6028. Pridobljeno 2. februarja 2021.

semanticscholar.org

api.semanticscholar.org

Shahhosseini, Nariman; Babuadze, George; Wong, Gary; Kobinger, Gary (2021). »Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern«. Microorganisms. 9 (5): 926. doi:10.3390/microorganisms9050926. PMC 8146828. PMID 33925854. S2CID 233460887.
Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, in sod. (november 2020). »A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology«. Nature Microbiology. 5 (11): 1403–1407. doi:10.1038/s41564-020-0770-5. PMC 7610519. PMID 32669681. S2CID 220544096.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava) Cited in (Alm et al.)
Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, in sod. (Junij 2021). »Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis«. BMJ. 373: n1412. doi:10.1136/bmj.n1412. PMC 8204098. PMID 34130987. S2CID 235187479.
Freitas AR, Lemos DR, Beckedorff OA, Cavalcanti LP, Siqueira AM, Mello RC, in sod. (19. april 2021). »The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P.1 was greater among young adults without pre-existing risk conditions«. medRxiv (Preprint). doi:10.1101/2021.04.13.21255281. S2CID 233295278. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95% CI, 2.9-11.03; p <0.0001) and in the age group of 40 and 59 years old, this risk was 7.7 times higher (95% CI, 5.01-11.83; p <0.0001) comparing with November–December. ... The heterogeneity observed between the age groups was greater when we analysed the subgroup of the population without preexisting risk conditions where we found that the CFR in the female sex in the second wave was 1.95 times (95% CI, 1.38-2.76) the CFR of the first wave in the population over 85 years old and was 7.7 times (95% CI, 5.01-11.83; p < 0.0001) in the population between 40 and 59 years old. In the male population without previous diseases, the CFR in the second wave was 2.18 (95% CI, 1.62-2.93) times the CFR of the first wave in the population over 85 years old and 5.9 (95% CI, 3.2-10.85; p < 0, 0001) higher in the range between 20 and 39 years old.
Fisman D, Tuite A (12. julij 2021). »Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada«. medRxiv (Preprint). doi:10.1101/2021.07.05.21260050. S2CID 235756602.

ssi.dk

covid19.ssi.dk

»Delta-PCR-testen« [The Delta PCR Test] (v danščini). Statens Serum Institut. 25. februar 2021. Pridobljeno 27. februarja 2021.

files.ssi.dk

»Status for udvikling af SARS-CoV-2 Variants of Concern (VOC) i Danmark« [Status of development of SARS-CoV-2 Variants of Concern (VOC) in Denmark] (v danščini). Statens Serum Institut. 27. februar 2021. Pridobljeno 27. februarja 2021.

statnews.com

»Don't call it the 'British variant.' Use the correct name: B.1.1.7«. STAT (v ameriški angleščini). 9. februar 2021. Pridobljeno 12. februarja 2021.
Helen Branswell The name game for coronavirus variants just got a little easier 31 May 2021 www.statnews.com, dostop: 28. 6. 2021

theconversation.com

O'Neill, Luke. »Mu: everything you need to know about the new coronavirus variant of interest«. The Conversation (v angleščini). Pridobljeno 3. septembra 2021.

twitter.com

»Today, @WHO announces new, easy-to-say labels for #SARSCoV2 Variants of Concern (VOCs) & Interest (VOIs)« (v angleščini). Pridobljeno 7. julija 2021.

usatoday.com

»South Africa finds omicron 'highly transmissible' and more resistant to COVID-19 vaccines«. USA Today. 14. december 2021. Pridobljeno 14. decembra 2021.

virological.org

Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, in sod. (18. december 2020). »Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations«. Virological. Pridobljeno 14. junija 2021.

web.archive.org

»Delta bolj nalezljiva od drugih različic virusa SARS-CoV-2«. NIJZ. 1. julij 2021. Arhivirano iz prvotnega spletišča dne 7. julija 2021. Pridobljeno 8. julija 2021.
»Nextclade« (What are the clades?). nextstrain.org. Arhivirano iz spletišča dne 19. januarja 2021. Pridobljeno 19. januarja 2021.
»SARS-CoV-2 Variant Classifications and Definitions«. CDC.gov. Centers for Disease Control and Prevention. 11. februar 2020. Arhivirano iz spletišča dne 29. junija 2021. Pridobljeno 18. junija 2021. Se redno posodablja.
»Tracking SARS-CoV-2 variants«. who.int (v angleščini). World Health Organization. Arhivirano iz spletišča dne 18. junija 2021. Pridobljeno 22. junija 2021. Se redno posodablja.
»Variants: distribution of cases data«. Public Health England. Government Digital Service. Arhivirano iz spletišča dne 7. junija 2021. Pridobljeno 16. februarja 2021.
»B.1.525 international lineage report«. cov-lineages.org. Pango team. 19. maj 2021. Arhivirano iz spletišča dne 9. junija 2021. Pridobljeno 16. februarja 2021.
»SARS-CoV-2 variants of concern«. ECDC.eu. European Centre for Disease Prevention and Control. Arhivirano iz spletišča dne 16. junija 2021. Pridobljeno 12. maja 2021. USe redno posodablja.
»Living Evidence – SARS-CoV-2 variants«. Agency for Clinical Innovation. nsw.gov.au. Ministry of Health (New South Wales). 23. julij 2021. Arhivirano iz spletišča dne 16. aprila 2021. Pridobljeno 22. marca 2021. Se redno posodablja..

who.int

WHO Headquarters (8. januar 2021). »3.6 Considerations for virus naming and nomenclature«. SARS-CoV-2 genomic sequencing for public health goals: Interim guidance, 8 January 2021. World Health Organization. str. 6. Pridobljeno 2. februarja 2021.
World Health Organization (15. januar 2021). »Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic«. Pridobljeno 18. januarja 2021.
»Tracking SARS-CoV-2 variants«. who.int (v angleščini). World Health Organization. Arhivirano iz spletišča dne 18. junija 2021. Pridobljeno 22. junija 2021. Se redno posodablja.
»Tracking SARS-CoV-2 variants«. SZO. Pridobljeno 8. julija 2021.
»Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern«. Svetovna zdravstvena organizacija. 26. november 2021. Pridobljeno 26. novembra 2021.

wionews.com

»COVID-19: Lambda variant may be more resistant to vaccines than other strains«.